Xtandi tablets contain enzalutamide as the active ingredient, which is classified as a nonsteroidal antiandrogen. This medication functions by selectively inhibiting the binding of male hormones known as androgens to androgen receptors found in prostate tissues. This disruption of the signaling pathway effectively impedes the progression of prostate cancer.
Xtandi's mechanism of action primarily revolves around its ability to act as an antagonist to androgen receptors in prostate cancer cells. These receptors play a pivotal role in transmitting signals that stimulate the growth and survival of cancerous prostate tissue. Enzalutamide binds to these receptors and prevents their activation, disrupting the androgen-driven cellular processes that fuel the malignancy and thereby inhibiting cancer growth.
In addition to its direct interference with androgen receptors, Xtandi demonstrates additional anti-tumor properties by targeting various proliferative pathways within prostate cancer cells. This multifaceted approach to cancer treatment makes Xtandi a valuable option for individuals dealing with metastatic or castration-resistant prostate cancer, which refers to a form of the disease that continues to progress despite reduced testosterone levels resulting from standard androgen deprivation therapy.
Clinical trials have provided valuable insights into the effectiveness of Xtandi tablets. For patients who have not undergone chemotherapy, the use of Xtandi has been associated with a statistically significant 30% reduction in the risk of death compared to receiving placebo treatments. Moreover, Xtandi has exhibited an impressive 81% reduction in radiographic progression, highlighting its ability to slow the spread of the disease within the body.
It is worth mentioning that Xtandi tablets may also have potential applications in feminizing hormone therapy for transgender women. This off-label use is based on the medication's antiandrogenic properties, which can assist in achieving desired changes in secondary sexual characteristics. However, transgender individuals considering this use should consult with a healthcare provider to evaluate its appropriateness and potential side effects. While Xtandi offers therapeutic benefits, it is crucial to exercise caution when considering its use. Pregnant women should avoid this medication, as it has the potential to harm the developing fetus. Therefore, it is advisable to discuss and implement adequate contraception measures during the treatment.
Active principles: enzalutamide
Amount: 28 tablets
Maker: Astellas Pharma Inc., Tokyo, Japan
Indications: treatment of castration-resistant prostate cancer and metastatic prostate cancer
Adults should take 2 tablets (160 mg of the active principle) at a time, once a day.
Contraindications: do not use for the following patients:
Due to teratogenic effect, this medicine should not be used for pregnant women or those who may become pregnant.
As in rare cases, this medicine may cause convulsive seizure, patient should pay close attention when operating dangerous machinery, driving a car or working at heights.
As this medicine may cause interstitial lung disease, initial symptoms such as shortness of breath, respiratory distress, cough or fever should be regularly checked while using this medicine. Patients is recommended to receive regular chest X-ray. If any of these initial symptoms of interstitial lung disease occur, patient should consult with medical institution immediately.
If an allergic reaction occurs, patient needs to stop using the medicine and consult with their doctor. If patient is taking any other medication or treatment, they should consult with their doctor in advance.
